Optimizing the collagenase G (ColG):collagenase H (ColH) ratio is a key strategy for achieving tailored donor-tissue specific islet isolation. Collagen V (Col V) and collagen III (Col III) are crucial target matrices of ColG and ColH, respectively. We herein investigated the relevance between the expression of target matrices in pancreatic tissues and influence of ColG:ColH ratio on islet isolation outcome. Islet isolation was performed in Lewis and SD rats using different ColG:ColH ratios (5:1, 1:1 and 1:5; n = 7/group). The composition of Col III and Col V was examined using immunohistochemical staining, real-time polymerase chain reaction (PCR), Western blotting and mass spectrometry. Chain types in collagen I (Col I) were also assessed using mass spectrometry. No beneficial effects were observed by increasing the ColG amount, irrespective of the rat strain. In contrast, the islet yield in Lewis rats was considerably increased by high amounts of ColH but decreased in SD rats, suggesting that Lewis pancreas contains more Col III than SD pancreas. Neither immunohistochemical nor real-time PCR showed correlation with isolation outcome. However, Western blotting revealed that Lewis contained considerably higher amount of Col III than SD (p = 0.10). Likewise, Col-I(α1)/Col-III(α1) and Col-I(α2)/Col-III(α1) were significantly lower in Lewis than in SD rats (p = 0.007, respectively). Furthermore, the isolation outcome was considerably correlated with the composition of homotrimeric Col I. The Col III expression and the composition of homotrimeric Col I in pancreatic tissues determined using mass analyses appeared useful for optimizing the ColG:ColH ratio in islet isolation.
Objective: This study examined the predictive value of flavin mononucleotide (FMN) levels in the flush solution used during cold storage of donor livers on outcomes post-transplantation. Background: Static cold storage for liver grafts induces hypoxia with subsequent impaired mitochondrial function and flavin mononucleotide (FMN) release upon reperfusion. Methods: This study enrolled 62 recipients who received whole liver grafts from donation after brain death (n=50) and circulatory death donors (n=12) between June 2022 and July 2023. FMN concentrations were measured in flush solutions on the back-table. The ROC-curve analysis identified an FMN level cutoff for graft survival. Post-transplant outcomes were examined according to FMN levels. Results: FMN level was significantly associated with graft survival, with an area under the curve of 0.858 (95% CI: 0.754–0.963, P <0.001), outperforming the donor risk index (area under the curve: 0.571, 95% CI: 0.227–0.915, P =0.686). The study cohort was divided into low-FMN (<37.5 ng/mL, n=40) and high-FMN groups (≥37.5 ng/mL, n=22). The low-FMN group had superior 1-year graft survival compared with the high-FMN group (100% vs 77%, P =0.003). Levels of transaminases within 7 days post-transplant were significantly higher in the high-FMN group ( P =0.003). The high-FMN group developed acute rejections (41% vs 15%, P =0.023) and early allograft dysfunction (50% vs 20%, P =0.014) more frequently. The median comprehensive complication index in the high-FMN group was significantly higher [54 (interquartile range, 40–78) vs 42 (interquartile range, 28–52), P =0.017]. Conclusions: The FMN level measured in donor livers’ cold storage flush solution is a valid biomarker to predict post-transplant outcomes. Liver grafts with high FMN levels may benefit from machine perfusion to improve outcomes.
Background/Objectives: The use of extended-criteria donors (ECDs) is rapidly increasing, with higher risks for impaired outcomes after liver transplantation (LT). Normothermic machine perfusion (NMP) can enhance graft viability assessment, though lactate clearance as a viability marker lacks consensus in clinical practice. Methods: This study analyzed 213 adult liver transplants using NMP from October 2022 to January 2024. Perfusate lactate levels were measured with an Epoc® reader and five lactate-based viability criteria were evaluated for predicting post-LT outcomes. Results: All livers cleared lactate at 6 h of NMP (median 0.51 mmol/L). However, 33 livers failed at least one lactate viability criterion. Thirteen livers (6.1%) were discarded based on traditional criteria, but discard rates would have been higher using Groningen (14.6%) or Brisbane (11.2%) criteria for lactate. Outcomes for the recipients of livers that failed the lactate criteria were comparable to those of recipients with livers meeting all criteria, including biliary complications (p = 0.63), graft survival (>0.99), and 6-month CCI (p = 0.89). ROC analysis revealed poor predictive value for graft survival for lactate clearance criteria (AUC 0.50), while lactate was outperformed by MEAF score (AUC 0.67). Conclusions: Lactate clearance alone does not predict outcomes, highlighting the need for further validation of alternative viability.
Background.: Augmentation of hepatic venous outflow is crucial in living donor liver transplantation (LDLT) to maximize functional graft size and prevent venous complications. We present details of our outflow augmentation technique for left lobe grafts (LLG) in adult LDLTs, which uses all recipient 3 hepatic veins and venoplasty of graft left and middle hepatic veins. This study examines the effectiveness of our technique in preventing outflow complications and the correlation between anatomical variations of the graft hepatic veins and surgical outcomes. Methods.: We retrospectively reviewed 88 patients who underwent LLG-LDLT between 2012 and 2023. The patients were classified into 3 groups based on the graft hepatic vein anatomy and usage of venoplasty: group 1 (n = 10, common trunk without venoplasty), group 2 (n = 62, common trunk with venoplasty), and group 3 (n = 16, no common trunk with venoplasty). Results.: No patient developed clinically significant venous outflow complications or graft loss related to venous outflow. There were no significant differences in complication rates or ascites production among the groups. Five-year graft survival was comparable among the groups (P = 0.43). Multiple regression analysis revealed that the model for end-stage liver disease score was the only independent risk factor for increased ascites after transplant (standardized beta, 0.546; t value,4.20; P < 0.001; 95% confidence interval, 0.287-0.804), but anatomical variations of the graft hepatic veins did not influence ascites output. Conclusions.: The recipient 3 hepatic vein outflow augmentation technique with graft venoplasty can be applied to various graft hepatic venous anatomy and effectively prevents outflow-related graft loss in LLG-LDLT.